Original Paper Dermatology 2014;228:240–249 DOI: 10.1159/000357807
Received: August 26, 2013 Accepted after revision: December 5, 2013 Published online: March 5, 2014
Circulating Autoantibodies and Autoimmune Comorbidities in Vitiligo Patients: A Multicenter Italian Study Vito Ingordo a, l Simone Cazzaniga c Beatrice Raone d Maria Donata Digiuseppe b, l Maria Letizia Musumeci e, l Dario Fai f, l Michele Pellegrino g, l Enrico Pezzarossa h, l Vito Di Lernia i, l Vincenzo Claudio Battarra j, l Riccardo Sirna k, l Annalisa Patrizi d, l Luigi Naldi c, l a
Outpatient Department of Dermatology, District No. 6, Health Local Unit, and b Department of Dermatology, ‘SS. Annunziata’ Hospital, Taranto; c Centro Studi GISED, Fondazione per la Ricerca Ospedale Maggiore, Bergamo; d Dermatology – Department of Experimental, Diagnostic and Specialized Medicine, University of Bologna, Bologna; e Department of Dermatology, P.O. ‘G. Rodolico’, A.O.U. Policlinico – Vittorio Emanuele, University of Catania, Catania; f Outpatient Department of Dermatology, ‘Romasi’ Hospital, Gagliano del Capo; g Department of Dermatology, University of Siena, Siena; h Department of Dermatology, Istituti Ospitalieri di Cremona, Cremona; i Dermatology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia; j Department of Dermatology, ‘S. Sebastiano e S. Anna’ Hospital, Caserta; k Department of Dermatology, Health Local Unit Hospital, Grosseto; l Dermatoepidemiology and Evidence Based Dermatology Study Group of ADOI, Italy
Abstract Background: Autoimmune comorbidities and circulating autoantibodies have been observed in vitiligo patients, but differences in rate are present according to countries in which the studies were performed, perhaps owing to ethnic diversities or different trigger factors. Objective: To estimate the prevalence of circulating autoantibodies and overt autoimmune diseases in a fairly large sample of Italian vitiligo patients. Methods: 175 outpatients affected by vitiligo and referred to nine dermatological centers were included in the study. Patients were offered routine blood test, serological testing for thyroid function and search for autoantibodies. Results: At least one circulating autoantibody was detected
© 2014 S. Karger AG, Basel 1018–8665/14/2283–0240$39.50/0 E-Mail [email protected] www.karger.com/drm
in 61 (41.8%) of 146 subjects who underwent laboratory tests. Anti-thyroperoxidase (25.6%), anti-thyroglobulin (23.4%), antinuclear antibodies (16.8%) and anti-gastric parietal cell antibodies (7.8%) were the most noticed autoantibodies. 74 (41.5%) autoimmune comorbidities, mainly autoimmune thyroiditis (37%), were reported. Conclusion: The prevalence of autoimmune comorbidities and circulating autoantibodies in this study was in agreement with other surveys conducted on Caucasian patients. © 2014 S. Karger AG, Basel
Introduction
It has been stated that patients with vitiligo have an increased risk of developing autoimmune diseases: a history and/or clinical findings of thyroid diseases, diabetes mellitus, pernicious anemia, Addison’s disease and autoVito Ingordo, MD Outpatient Department of Dermatology District No. 6, Taranto Health Local Unit Via B. Calati, IT–74026 Pulsano, Taranto (Italy) E-Mail vito.ingordo @ alice.it
Downloaded by: George Mason University Fenwick Library 198.143.37.1 - 3/10/2016 6:22:02 PM
Key Words Circulating autoantibodies · Autoimmune comorbidities · Vitiligo · Multicenter Italian study
main factors. The influence of selected factors was expressed in terms of odds ratios along with 95% confidence intervals and p values. Statistical differences were considered significant at a p value
Received: August 26, 2013 Accepted after revision: December 5, 2013 Published online: March 5, 2014
Circulating Autoantibodies and Autoimmune Comorbidities in Vitiligo Patients: A Multicenter Italian Study Vito Ingordo a, l Simone Cazzaniga c Beatrice Raone d Maria Donata Digiuseppe b, l Maria Letizia Musumeci e, l Dario Fai f, l Michele Pellegrino g, l Enrico Pezzarossa h, l Vito Di Lernia i, l Vincenzo Claudio Battarra j, l Riccardo Sirna k, l Annalisa Patrizi d, l Luigi Naldi c, l a
Outpatient Department of Dermatology, District No. 6, Health Local Unit, and b Department of Dermatology, ‘SS. Annunziata’ Hospital, Taranto; c Centro Studi GISED, Fondazione per la Ricerca Ospedale Maggiore, Bergamo; d Dermatology – Department of Experimental, Diagnostic and Specialized Medicine, University of Bologna, Bologna; e Department of Dermatology, P.O. ‘G. Rodolico’, A.O.U. Policlinico – Vittorio Emanuele, University of Catania, Catania; f Outpatient Department of Dermatology, ‘Romasi’ Hospital, Gagliano del Capo; g Department of Dermatology, University of Siena, Siena; h Department of Dermatology, Istituti Ospitalieri di Cremona, Cremona; i Dermatology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia; j Department of Dermatology, ‘S. Sebastiano e S. Anna’ Hospital, Caserta; k Department of Dermatology, Health Local Unit Hospital, Grosseto; l Dermatoepidemiology and Evidence Based Dermatology Study Group of ADOI, Italy
Abstract Background: Autoimmune comorbidities and circulating autoantibodies have been observed in vitiligo patients, but differences in rate are present according to countries in which the studies were performed, perhaps owing to ethnic diversities or different trigger factors. Objective: To estimate the prevalence of circulating autoantibodies and overt autoimmune diseases in a fairly large sample of Italian vitiligo patients. Methods: 175 outpatients affected by vitiligo and referred to nine dermatological centers were included in the study. Patients were offered routine blood test, serological testing for thyroid function and search for autoantibodies. Results: At least one circulating autoantibody was detected
© 2014 S. Karger AG, Basel 1018–8665/14/2283–0240$39.50/0 E-Mail [email protected] www.karger.com/drm
in 61 (41.8%) of 146 subjects who underwent laboratory tests. Anti-thyroperoxidase (25.6%), anti-thyroglobulin (23.4%), antinuclear antibodies (16.8%) and anti-gastric parietal cell antibodies (7.8%) were the most noticed autoantibodies. 74 (41.5%) autoimmune comorbidities, mainly autoimmune thyroiditis (37%), were reported. Conclusion: The prevalence of autoimmune comorbidities and circulating autoantibodies in this study was in agreement with other surveys conducted on Caucasian patients. © 2014 S. Karger AG, Basel
Introduction
It has been stated that patients with vitiligo have an increased risk of developing autoimmune diseases: a history and/or clinical findings of thyroid diseases, diabetes mellitus, pernicious anemia, Addison’s disease and autoVito Ingordo, MD Outpatient Department of Dermatology District No. 6, Taranto Health Local Unit Via B. Calati, IT–74026 Pulsano, Taranto (Italy) E-Mail vito.ingordo @ alice.it
Downloaded by: George Mason University Fenwick Library 198.143.37.1 - 3/10/2016 6:22:02 PM
Key Words Circulating autoantibodies · Autoimmune comorbidities · Vitiligo · Multicenter Italian study
main factors. The influence of selected factors was expressed in terms of odds ratios along with 95% confidence intervals and p values. Statistical differences were considered significant at a p value
